Syllabus: PSYCH501 Psychological Approaches to Depression and Schizophrenia

Session 1: Introduction to Psychopathology & Defining Normality

Session Duration: 2 Hours (120 mins)

Teacher's Checklist

1. Introduction to Psychopathology (15 mins)

Welcome to PSYCH501. This unit delves into two of the most significant and complex mental health disorders: depression and schizophrenia. We will explore how these conditions are defined, diagnosed, and understood from various psychological and biological perspectives. The core aim is to develop a critical understanding of the theoretical frameworks and the practical application of therapies. Psychopathology is the scientific study of mental disorders, including efforts to understand their genetic, biological, psychological, and social causes (their aetiology). It is a field that requires both scientific rigour and deep empathy.

2. Evaluating the Process of Defining Normality and Abnormality (75 mins)

The concept of "abnormality" is fundamental to psychopathology, yet it is notoriously difficult to define. There is no single, universally accepted definition. Instead, psychologists use several frameworks, each with its own strengths and limitations. Critically evaluating these definitions (AC 1.1) is the first step in understanding psychiatric diagnosis.

A. Statistical Infrequency

This definition views abnormality as any behaviour or characteristic that is statistically rare or uncommon in a given population. It is based on the idea of a normal distribution curve, where the majority of people cluster around the mean, and those at the extremes are considered "abnormal."

Example: If the average IQ is 100, individuals with an IQ below 70 (intellectual disability) or above 130 (giftedness) are statistically infrequent.
Evaluation:
Strength: It provides a clear, objective, and quantitative cut-off point, making it useful for diagnostic assessment.
Limitation 1: It fails to distinguish between desirable and undesirable rarity. High intelligence is rare but is not a disorder requiring treatment.
Limitation 2: Some common conditions, like depression or anxiety, are too frequent to be considered "statistically rare" (affecting up to 1 in 6 people), yet are clearly forms of psychopathology.

B. Deviation from Social Norms

Every society has explicit rules (laws) and implicit, unwritten rules (social norms) about acceptable behaviour. Behaviour that violates these norms is considered abnormal. This definition is rooted in the social context.

Example: In many Western cultures, talking loudly to oneself in public would be seen as deviating from social norms. In some historical contexts, women pursuing higher education was seen as a deviation.
Evaluation:
Strength: It is contextually relevant and considers the situational appropriateness of behaviour. It helps distinguish between eccentric but harmless behaviour and socially problematic behaviour.
Limitation 1 (Cultural Relativism): What is normal in one culture may be abnormal in another (e.g., hearing voices of ancestors may be a respected spiritual experience in some cultures but a symptom of schizophrenia in others).
Limitation 2 (Era-Dependent): Norms change over time. Homosexuality was listed as a mental disorder in the DSM until 1973, a clear example of this definition being used to enforce prevailing social attitudes.

3. Interactive & Application Activities (30 mins)

• Mini Activity (10 mins): In pairs using online breakout rooms, students list three behaviours that are statistically infrequent but not a disorder, and three behaviours that are common but could be symptomatic of a disorder. Discuss upon return.
• Classroom Application (20 mins): Use an online poll (e.g., Mentimeter, Poll Everywhere). Present a short scenario: "A man in his 40s quits his high-paying job to live in a remote cabin with no electricity, spending his days writing poetry. Is this abnormal?" Ask students to vote 'Yes', 'No', or 'It's complicated' and then facilitate a discussion where they justify their answers using the two definitions covered today.

4. Distinction-Level Thinking

Analytical Question: ";To what extent is the concept of 'social norms' a valid basis for psychiatric diagnosis, considering its potential for cultural bias and social control?"

5. Useful Resources

• Article: Pilgrim, D. (2000). The social construction of mental illness. In T. Heller et al. (Eds.), Mental Health Matters. Palgrave. (Provides a good overview of the social context).
• Video: "On Being Sane In Insane Places: The Rosenhan Experiment" - A summary of the classic study questioning diagnostic labels. Watch on YouTube

Session 2: Defining Abnormality - Functional & Ideal Mental Health Approaches

Session Duration: 2 Hours (120 mins)

Teacher's Checklist

1. Failure to Function Adequately (FFA) (45 mins)

This definition considers abnormality in terms of an individual's inability to cope with the demands of everyday life. The focus is on how the individual is managing from a practical, functional perspective. Rosenhan & Seligman (1989) proposed several features of FFA:

• Personal Distress: The individual experiences significant suffering, anxiety, or upset.
• Maladaptive Behaviour: Behaviour that prevents the individual from achieving major life goals (e.g., holding a job, maintaining relationships, personal care).
• Unpredictability & Irrationality: Behaviour that is erratic, uncontrolled, or incomprehensible to others.
• Observer Discomfort: Behaviour that causes significant discomfort or distress to others who witness it.

Example 1 (Clear FFA): A person with severe agoraphobia who has not left their house in years is unable to work, shop for food, or socialise. This is a clear failure to function.
Example 2 (Complex Case): A high-functioning professional who suffers from severe panic attacks but manages to hide them from colleagues. They are functioning at work but experiencing intense personal distress. FFA captures this distress.
Evaluation:
Strength: It is patient-centric, considering their subjective experience and practical difficulties. It provides a practical threshold for seeking professional help.
Limitation: It's a value judgment. Who decides what is "adequate"? Some people may choose an unconventional lifestyle (e.g., living as a hermit) that others might see as "failing to function," but which is a conscious choice and causes no distress to the individual.

2. Deviation from Ideal Mental Health (45 mins)

This approach takes a different, more positive perspective. Instead of defining what is abnormal, it defines what is normal or "ideal" and considers any deviation from this ideal as abnormal. Marie Jahoda (1958) identified six criteria for ideal mental health:

1. Positive self-attitude: Having high self-esteem and a strong sense of identity.
2. Self-actualisation: Striving to reach one's full potential.
3. Autonomy: Being independent, self-reliant, and able to make one's own decisions.
4. Resistance to stress: Having effective coping strategies and psychological resilience.
5. Accurate perception of reality: Seeing the world and oneself without distortion.
6. Environmental mastery: Being able to meet the demands of any situation, adapt, and function effectively in various roles (work, relationships).

Example: A person who is highly dependent on others for validation (lacks autonomy) and has a very pessimistic view of the world (inaccurate perception of reality) would be deviating from this ideal.
Evaluation:
Strength: It is a positive, holistic approach that focuses on desirable goals and what it means to be psychologically healthy.
Limitation 1 (Unrealistic Standard): The criteria are extremely demanding. By this definition, most people would be considered "abnormal" at some point in their lives, as few can achieve all six criteria simultaneously and permanently.
Limitation 2 (Cultural Bias): The criteria are heavily biased towards Western, individualistic ideals (e.g., autonomy, self-actualisation). In collectivist cultures, interdependence may be valued more than autonomy.

3. Interactive & Application Activities (30 mins)

• Interactive Exercise (15 mins): Present a short case study of a fictional character (e.g., a successful but highly anxious CEO who works 80 hours a week and has no social life). In an online collaborative document (like Google Docs), students must list which criteria of FFA and Ideal Mental Health the character meets or fails to meet.
• Classroom Application (15 mins): In a whole-class discussion, debate: "Which of the four definitions of abnormality (Statistical, Social Norms, FFA, Ideal Mental Health) is most useful for a practicing clinical psychologist and why?" Encourage students to argue that a combination is likely used.

4. Distinction-Level Thinking

Analytical Question: ";Critically evaluate the claim that all definitions of abnormality are culturally bound. Can a universal definition of psychopathology ever be achieved, or is it an impossible goal?"

5. Useful Resources

• Article: Rosenhan, D. L. (1973). On being sane in insane places. Science, 179(4070), 250-258. (A classic study questioning the validity of psychiatric diagnosis).
• Video: TED-Ed: "What is depression?" by Helen M. Farrell. This video provides a good example of symptoms that relate to 'Failure to Function Adequately'. Watch on YouTube

Session 3: Schizophrenia - Clinical Characteristics and Diagnosis

Session Duration: 2 Hours (120 mins)

Teacher's Checklist

1. Introduction to Schizophrenia (20 mins)

Schizophrenia is a severe and chronic mental disorder characterized by profound disruptions in thinking, affecting language, perception, and the sense of self. It often includes psychotic experiences, such as hearing voices or holding delusional beliefs. It is crucial to dispel common myths: it is not a "split personality." The term, coined by Eugen Bleuler, means "split mind," referring to the fragmentation or 'splitting' of mental functions like thought, emotion, and perception from each other.

2. Clinical Characteristics: Positive and Negative Symptoms (60 mins)

The symptoms of schizophrenia are typically categorized as positive or negative. This does not mean 'good' or 'bad'.

• Positive Symptoms: These are experiences and behaviours that are added to the person's normal functioning, or are an excess/distortion of normal functions.
  • Hallucinations: Perceptual experiences that occur without an external stimulus. Example: A person hearing voices that comment on their actions or give them commands when no one is there. While auditory hallucinations are most common, they can be visual, olfactory, or tactile.
  • Delusions: Fixed, false beliefs that are resistant to reason or contradictory evidence, and are not in keeping with the person's culture. Example: A delusion of persecution, where a person believes their colleagues are plotting to poison them.
  • Disorganised Speech (Thought Disorder): Jumbled and incoherent speech that reflects confused thinking. Example: A person might switch from one topic to another without any logical connection (derailment) or speak in a "word salad".

• Negative Symptoms: These represent a loss or deficit in normal functioning. They are often more persistent and cause more long-term impairment.
  • Alogia (Poverty of Speech): A reduction in the amount or content of speech. Example: When asked a question, the person gives very brief, empty replies.
  • Avolition (Apathy): A severe lack of motivation to engage in purposeful activities. Example: A person may sit for hours, showing no interest in work, hobbies, or personal hygiene.
  • Affective Flattening: A reduction in the range and intensity of emotional expression. Example: The person may speak in a monotonous voice and have a blank facial expression.

C. Further Symptom Dimensions: Disorganised Behaviour and Catatonia

Beyond the classic positive and negative symptoms, clinicians also assess two further symptom dimensions that are highly clinically significant.

• Grossly Disorganised Behaviour: This refers to a wide range of behaviours that are not goal-directed. A person may have great difficulty performing everyday tasks, respond inappropriately in social situations (e.g., laughing when receiving bad news), display unpredictable agitation, or neglect personal hygiene entirely. This symptom is classed as a positive symptom because it represents an excess of abnormal behaviour. Clinical Note: Disorganised behaviour should be distinguished from substance intoxication, which can appear superficially similar.
• Catatonic Behaviour: Catatonia is a syndrome of motor abnormalities that can range dramatically. At one extreme, there is catatonic stupor – a state of apparent unawareness and unresponsiveness where the person may remain motionless for hours. At the other extreme is catatonic excitement – purposeless, agitated motor activity. Intermediate features include: waxy flexibility (a person's limbs can be placed in strange positions, which they will hold for long periods), echolalia (meaningless repetition of another person's speech), and echopraxia (copying another person's movements). Catatonia is considered a positive symptom because it involves the addition of abnormal motor patterns to the person's behaviour.

D. Schneiderian First-Rank Symptoms (Key for ICD-10)

German psychiatrist Kurt Schneider (1959) proposed a set of First-Rank Symptoms (FRS) which he argued were highly specific to schizophrenia – meaning, if you had them, a diagnosis was almost certain. The ICD-10 diagnostic system places particular emphasis on these. They include:

• Thought Insertion: The belief that thoughts have been put into one's mind by an external force. Example: "The Russians are planting ideas in my head."
• Thought Withdrawal: The belief that one's thoughts are being taken out of one's mind. Example: "I was thinking normally and then my thoughts just vanished – someone took them."
• Thought Broadcast: The belief that one's private thoughts are being transmitted to others so they can hear them. This is distinct from talking aloud; the person believes their private mental contents are publicly accessible.
• Delusional Perception: A normal perception is suddenly given a delusional and highly significant meaning. Example: A person sees a white car drive past and immediately knows, with absolute certainty, that they have been chosen to save the world.
• Voices Commenting or Discussing: Hearing two voices talking about you in the third person, or a voice providing a running commentary on your actions.

Evaluation of First-Rank Symptoms: Schneider's FRS are influential in diagnosis but have been criticised on several counts. First, they have limited specificity: they also occur in bipolar disorder (with psychosis), making them less diagnostically exclusive than Schneider claimed. Second, studies have found low inter-rater reliability for identifying these specific symptoms, particularly across different cultures. Third, the DSM-5 removed FRS as special criteria, reflecting a shift away from this framework. Nevertheless, they remain clinically valuable for guiding clinical reasoning, especially when using ICD-10.

3. Diagnostic Criteria (20 mins)

Two main classification systems are used: the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, 5th Edition) and the ICD-10 (International Classification of Diseases, 10th Edition).

• DSM-5 Criteria: Requires at least two symptoms from a list (one must be delusions, hallucinations, or disorganised speech) for a significant portion of time during a 1-month period. There must also be social/occupational dysfunction, and continuous signs of disturbance for at least 6 months. The DSM-5 dropped the classic subtypes of schizophrenia (e.g., paranoid, catatonic), reflecting research evidence that these subtypes had poor reliability and limited clinical utility. The recognition of a spectrum of related psychotic disorders (Schizophrenia Spectrum) was a major innovation.
• ICD-10 Criteria: Has a greater emphasis on specific "first-rank" symptoms (e.g., thought insertion, delusional perception, as described above). It generally requires symptoms to be present for at least one month. The ICD-10 retains the subtypes (paranoid, hebephrenic, catatonic, undifferentiated, residual, simple), which are widely used in clinical practice outside North America. The upcoming ICD-11 moves closer to the DSM-5 approach by removing subtypes.

A Comparison of Approaches: The differences between DSM-5 and ICD-10 reflect genuine disagreements about how schizophrenia should be conceptualised. The DSM-5's dimensional approach (recognising that symptoms exist on a spectrum) may be more scientifically valid but can be harder for clinicians to apply day-to-day. The ICD-10's categorical subtypes, though criticised for poor reliability, provide clinicians and patients with a more specific, communicable label. This distinction itself illustrates the ongoing tension between reliability and validity in psychiatric classification.

4. Interactive & Application Activities (20 mins)

• Mini Activity (10 mins): Watch a short, anonymised video clip of a patient interview (if ethically sourced and available) or read a written vignette. Use the chat function to have students identify examples of positive and negative symptoms as they see them.
• Classroom Application (10 mins): In breakout rooms, provide groups with a short case study. Each group must use the DSM-5 criteria to decide if a diagnosis of schizophrenia is warranted, justifying their decision for each criterion.

5. Distinction-Level Thinking

Analytical Question: "Why is the distinction between positive and negative symptoms clinically important for both diagnosis and treatment planning?"

6. Useful Resources

• Website: American Psychiatric Association - What is Schizophrenia? Read here
• Article: American Psychiatric Association. (2013). *Diagnostic and statistical manual of mental disorders (5th ed.)*. See the section on Schizophrenia Spectrum and Other Psychotic Disorders. View DSM-5 Comparison Table
• Video: Stanford's Professor Robert Sapolsky Lecture on Schizophrenia. Watch on YouTube

Session 4: Issues in Diagnosing Schizophrenia - Reliability and Validity

Session Duration: 2 Hours (120 mins)

Teacher's Checklist

1. Reliability in Diagnosis (30 mins)

Reliability refers to the consistency of a measurement. In diagnosis, this primarily means inter-rater reliability: the extent to which different clinicians, using the same classification system, arrive at the same diagnosis for the same patient.
Historical Context: Early studies (e.g., Beck et al., 1962) found very poor inter-rater reliability for schizophrenia, with agreement as low as 54%. This was a major crisis for psychiatry.
Modern Context: The introduction of more specific, operationalised criteria in later versions of the DSM and ICD has significantly improved reliability. However, challenges remain.

2. Validity in Diagnosis (30 mins)

Validity refers to the accuracy of a measurement – whether it measures what it intends to measure. For a diagnosis to be valid, it should be a meaningful and distinct category. Key types of validity include:

• Predictive Validity: Does the diagnosis accurately predict the course of the illness and response to treatment? (Broadly yes for schizophrenia, which supports its validity).
• Descriptive Validity: Do patients with the same diagnosis exhibit distinct symptoms from patients with other diagnoses? (Challenged by symptom overlap).
• Aetiological Validity: Do all patients with the diagnosis share the same underlying causes? (Very weak for schizophrenia, which has many different causes).

3. Key Issues Affecting Reliability and Validity (40 mins)

• Co-morbidity: This is when a person has two or more disorders at the same time. Schizophrenia is frequently co-morbid with substance abuse (~47%) and depression (~50%), which complicates diagnosis.
• Symptom Overlap: Many symptoms of schizophrenia (e.g., delusions) are also found in other disorders like bipolar disorder, making differential diagnosis difficult.
• Cultural Bias: People of Afro-Caribbean descent in the UK and US are several times more likely to be diagnosed with schizophrenia than white people, suggesting clinicians may misinterpret culturally specific beliefs as psychotic symptoms.
• Gender Bias: Men tend to be diagnosed earlier than women (typically in their early-to-mid 20s, versus mid-to-late 20s for women). Women often have better social functioning prior to diagnosis, which may lead clinicians to under-diagnose or delay diagnosis. Women also tend to have better long-term outcomes, which may reflect hormonal factors (oestrogen may have a neuroprotective effect) or differences in social support networks. A further gender bias: women are more likely to be given a comorbid affective diagnosis (e.g., major depression) alongside schizophrenia, which can complicate treatment decisions.
• The Problem of "Pseudopatients": The Rosenhan (1973) Study: This landmark study remains one of the most powerful critiques of diagnostic validity. David Rosenhan had eight normal individuals (pseudopatients) present to different psychiatric hospitals, claiming to hear an unfamiliar voice saying "thud," "empty," and "hollow." All eight were admitted, and seven were diagnosed with schizophrenia (one with manic depression). Once admitted, the pseudopatients behaved entirely normally. Despite this, the average hospital stay was 19 days, and none of the pseudopatients were "unmasked" by staff (though real patients often suspected them). All were eventually discharged with a diagnosis of "schizophrenia in remission."
  Implications for Validity: The study demonstrated that (a) it was impossible to distinguish the sane from the insane once labelled, and (b) the psychiatric label "schizophrenia" stuck as a self-fulfilling prophecy – normal behaviours (taking notes, asking questions) were interpreted through the lens of the psychiatric label. A sceptical hospital challenged Rosenhan, claiming it could detect pseudopatients. Rosenhan agreed to send some, and the hospital identified 41 suspected impostors out of 193 admissions. In fact, Rosenhan sent no pseudopatients at all. This second part of the study illustrated the problem in the opposite direction – over-caution in diagnosis led to false negatives. Together, both findings demonstrate that the reliability and validity of psychiatric diagnosis are profoundly difficult to establish in real-world settings.
  Counter-Argument: The study has been criticised as methodologically problematic. Deliberately misleading clinicians undermines the validity of the findings. Furthermore, healthcare has changed significantly since 1973, with structured diagnostic interviews and DSM-5 criteria reducing reliance on clinical impression alone.

Improving Reliability and Validity: Modern Solutions

Contemporary psychiatry has developed several strategies to improve diagnostic reliability and validity:

• Operationalised Criteria: The move from ICD-8 (1967) to DSM-III (1980) and subsequent editions introduced highly detailed, operationalised criteria. This transformed psychiatry from relying on clinical impression to using explicit, checklist-style diagnostic rules. Studies comparing inter-rater reliability across DSM editions show a consistent improvement: from kappa values of ~0.4–0.5 (indicating moderate agreement) in early editions to ~0.6–0.7 (good agreement) in DSM-5 field trials for schizophrenia.
• Structured Clinical Interviews: Tools such as the SCID-5 (Structured Clinical Interview for DSM-5) and the Present State Examination (PSE) provide clinicians with a standardised set of probe questions, reducing the variability that arises from unstructured interviews. Research consistently shows that structured interviews improve inter-rater reliability compared to unstructured clinical conversations.
• Cultural Competency Training: Mental health services increasingly recognise the need for clinicians to be trained in cultural sensitivity. Tools like the DSM-5's Cultural Formulation Interview (CFI) provide a structured way to explore the cultural context of a patient's distress, reducing clinician bias. NICE guidelines now recommend that clinicians routinely ask about cultural and spiritual beliefs when assessing psychotic symptoms.
• The Research Domain Criteria (RDoC): Proposed by the National Institute of Mental Health (NIMH), the RDoC framework is a radical alternative to the categorical diagnostic approach. Rather than grouping patients by symptom clusters, it proposes grouping them by underlying biological and psychological processes (e.g., fear processing, working memory). This approach aims to create diagnoses with greater aetiological validity, though it is primarily a research framework at present.

4. Interactive & Application Activities (20 mins)

• Classroom Application (20 mins): Divide the class into four breakout groups. Assign each group one of the key issues (Co-morbidity, Symptom Overlap, Cultural Bias, Gender Bias). Their task is to explain how their assigned issue specifically challenges the reliability and validity of a schizophrenia diagnosis and propose one way to mitigate this issue in clinical practice.

5. Distinction-Level Thinking

Analytical Question: "Given the significant issues with validity and reliability, should schizophrenia be re-conceptualised as a 'spectrum disorder' rather than a single categorical diagnosis? Evaluate the pros and cons of such a shift."

6. Useful Resources

• Article: Aboraya, A., et al. (2006). The reliability of psychiatric diagnosis revisited: The clinician's guide to improve the reliability of psychiatric diagnosis. Psychiatry (Edgmont), 3(1), 41–50. Read on PMC
• Article: Kendell, R., & Jablensky, A. (2003). Distinguishing between the validity and utility of psychiatric diagnoses. American journal of Psychiatry, 160(1), 4-12. Read here

Session 5: Biological Explanations of Schizophrenia - Genetics

Session Duration: 2 Hours (120 mins)

Teacher's Checklist

1. The Role of Heredity in Schizophrenia (60 mins)

It has long been observed that schizophrenia tends to run in families, suggesting a genetic component. Research uses family, twin, and adoption studies to untangle the influence of genetics (nature) from environment (nurture).

• Family Studies: These studies examine the prevalence of schizophrenia among relatives. Research consistently shows that the closer the genetic relationship, the higher the risk (e.g., sibling risk is ~9% vs. 1% in the general population). Limitation: Families share environments as well as genes.
• Twin Studies: These compare concordance rates between monozygotic (MZ, identical) twins (100% shared genes) and dizygotic (DZ, fraternal) twins (~50% shared genes). Key Finding (Gottesman, 1991): A landmark review found a concordance rate of 48% for MZ twins and 17% for DZ twins. The higher MZ rate is strong evidence for a genetic component, but because it's not 100%, it proves genes are not the only factor.
• Adoption Studies: These are crucial for separating nature and nurture. They examine children adopted at a young age who have a biological parent with schizophrenia. Key Finding (Tienari et al., 2004): A Finnish study found that 6.7% of adoptees whose biological mothers had schizophrenia developed the disorder, compared to just 2% of a control group of adoptees.

2. The Diathesis-Stress Model (30 mins)

This is the most accepted modern framework. It proposes that individuals inherit a genetic vulnerability (a diathesis) to schizophrenia. However, the disorder will only develop if the individual is exposed to a significant environmental or psychological stressor (e.g., childhood trauma, family dysfunction, substance abuse).
Example: An individual might carry genes linked to schizophrenia (the diathesis) but lead a stable, low-stress life and never develop the disorder. Their identical twin, who experiences a traumatic event (the stress), might go on to develop schizophrenia. This model explains why the MZ concordance rate is not 100%.

3. Molecular Genetics: From Heritability to Specific Genes

While family, twin, and adoption studies establish that schizophrenia is heritable, they do not tell us which genes are involved. Molecular genetic research attempts to identify the specific gene variants that confer risk.

A. The Polygenic Model

Most researchers now accept that schizophrenia is polygenic, meaning it is caused by the combined action of hundreds or thousands of genes, each contributing a very small amount of risk. There is no single "schizophrenia gene." This contrasts with Mendelian (single-gene) disorders such as Huntington's disease. The polygenic model has important implications: it explains why the disorder is so prevalent (~1% of the global population), why it runs in families but does not follow a simple inheritance pattern, and why it overlaps genetically with other disorders like bipolar disorder and major depression.

B. Candidate Gene Studies

Researchers initially focused on candidate genes – genes with biological plausibility for involvement in schizophrenia, often selected because they are involved in neurotransmitter systems. Key candidates include:

• COMT (Catechol-O-methyltransferase): This gene codes for an enzyme that breaks down dopamine in the prefrontal cortex. A specific variant of the COMT gene (the Val158Met polymorphism) produces more efficient dopamine clearance and is associated with impaired prefrontal cognitive function, which maps onto the negative and cognitive symptoms of schizophrenia. This is one of the most studied candidate genes.
• DISC1 (Disrupted in Schizophrenia 1): A translocation mutation on chromosome 1 was found in a large Scottish family with unusually high rates of schizophrenia, major depression, and bipolar disorder. DISC1 is thought to be involved in neuronal development and function, and disruptions to this gene have been replicated in other cohorts, though effect sizes are modest.
• NRG1 (Neuregulin 1): This gene is involved in the development of the nervous system and glutamate receptor function. Variants of NRG1 have been associated with increased risk of schizophrenia in multiple studies, particularly in Icelandic and Irish populations. Its connection to the NMDA glutamate receptor pathway is particularly interesting given the glutamate hypothesis of schizophrenia.

Evaluation of Candidate Gene Studies: These studies have been criticised for poor replication. Many initial findings failed to hold up in larger, independent samples. This is partly because the effect size of any individual gene variant is very small (odds ratio of approximately 1.1–1.5), requiring extremely large samples to detect reliably. Publication bias (the tendency to publish positive findings more readily than null findings) has further inflated apparent effect sizes in early studies.

C. Genome-Wide Association Studies (GWAS)

A more systematic approach is the Genome-Wide Association Study (GWAS). Rather than testing specific candidate genes, GWAS scans hundreds of thousands of genetic variants simultaneously across the entire genome and compares their frequency in cases (people with schizophrenia) versus controls. This unbiased approach has yielded more robust findings:

• The largest meta-analysis to date (Trubetskoy et al., Nature, 2022) analysed data from over 76,755 cases and 243,649 controls. It identified 287 distinct loci (genomic locations) associated with schizophrenia risk. These loci collectively implicated synaptic and neuronal pathways, providing biological plausibility for the findings.
• The MHC region (Major Histocompatibility Complex) on chromosome 6 showed the strongest association. Variants in this region affect the complement component 4 (C4) gene, which is involved in synaptic pruning – the process by which the brain eliminates excess synaptic connections during adolescence. Over-active C4 may lead to excessive pruning of synaptic connections in the prefrontal cortex, contributing to the cognitive and negative symptoms of schizophrenia. This represents one of the most compelling biological mechanisms identified to date.

Evaluation of GWAS: GWAS has provided statistically robust associations, but several challenges remain. The findings have limited predictive power for any individual – knowing someone's genotype explains only a fraction of their statistical risk. Furthermore, most GWAS studies have been conducted on populations of European descent, limiting generalisability. The gap between identifying a risk locus and understanding its biological mechanism (the "variant-to-function" problem) also remains a significant challenge for translation into treatment.

3. Interactive & Application Activities (30 mins)

• Interactive Exercise (15 mins): Provide students with a simplified family tree showing members with and without schizophrenia. In breakout rooms, they must calculate the risk for a specific individual and explain why their risk is higher than the general population but less than 100%.
• Classroom Application (15 mins): Host a debate on the statement: "Genetic screening for schizophrenia would be beneficial for society." One side argues for (e.g., early intervention), the other against (e.g., ethical issues, stigma).

4. Distinction-Level Thinking

Analytical Question: ";If schizophrenia is polygenic (caused by multiple genes), what are the implications for developing a single 'cure' for the disorder? How does this support the diathesis-stress model?"

5. Useful Resources

• Article: Gottesman, I. I. (1991). *Schizophrenia genesis: The origins of madness*. Freeman. (A summary article of this classic text would be most accessible).
• Video: "The genetics of mental illness" by The Brain & Behavior Research Foundation. Watch on YouTube

Session 6: Biological Explanations of Schizophrenia - The Dopamine Hypothesis

Session Duration: 2 Hours (120 mins)

Teacher's Checklist

1. The Original Dopamine Hypothesis (30 mins)

The dopamine hypothesis suggests schizophrenia is caused by an excess of the neurotransmitter dopamine in the brain. The original version proposed a simple idea: too much dopamine (hyperdopaminergia) causes the symptoms.
Evidence:
1. Drug-Induced Psychosis: Large doses of amphetamines, which increase dopamine, can produce psychosis similar to the positive symptoms of schizophrenia.
2. Antipsychotic Medication: The first antipsychotics (e.g., chlorpromazine) work by blocking dopamine receptors (they are dopamine antagonists), which reduces positive symptoms.
Limitation: This simple model couldn't explain why antipsychotics were largely ineffective against negative symptoms.

2. The Revised Dopamine Hypothesis (45 mins)

Modern research has refined the theory. It is more complex and suggests that dopamine dysregulation is specific to certain brain pathways:

• Hyperdopaminergia in the Subcortex: An excess of dopamine in the mesolimbic pathway is believed to be responsible for the positive symptoms (hallucinations, delusions).
• Hypodopaminergia in the Prefrontal Cortex: A deficit of dopamine in the mesocortical pathway is thought to be responsible for the negative and cognitive symptoms (avolition, alogia).

This revised model better explains why patients can experience both positive and negative symptoms.

3. Evidence and Evaluation (45 mins)

Supporting Evidence:
• PET Scans: Studies show that patients with schizophrenia have a greater release of dopamine in response to amphetamines.
• Atypical Antipsychotics: Newer drugs that block both dopamine and serotonin receptors are often more effective against negative symptoms, suggesting the original hypothesis was too simplistic.
Contradictory Evidence & Evaluation:
• Role of Glutamate: Research suggests the root cause might be dysfunction in the glutamate system, which then leads to dopamine dysregulation.
• Correlation vs. Causation: It's difficult to know if dopamine dysregulation is a cause of schizophrenia or an effect of the disorder.
• Reductionist: Focusing only on dopamine ignores the complex interplay of genetic, psychological, and social factors.

Further Evidence: L-DOPA and Parkinson's Disease Research

An interesting line of evidence comes from the treatment of Parkinson's disease. Parkinson's is caused partly by the degeneration of dopaminergic neurons in the nigrostriatal pathway. Patients are treated with L-DOPA (levodopa), a precursor that is converted into dopamine in the brain, increasing dopamine levels. A well-documented side effect of prolonged or high-dose L-DOPA treatment is the development of psychosis, including visual hallucinations and paranoid delusions. This provides supporting evidence that elevated dopamine activity can produce psychotic symptoms similar to those in schizophrenia. Conversely, the neurological disease itself – characterised by dopamine depletion – involves impaired emotional expressiveness and reduced motivation, features reminiscent of negative symptoms. This neat "natural experiment" supports the revised dopamine hypothesis's division between high dopamine (positive symptoms) and low dopamine (negative symptoms).

The Glutamate Hypothesis: A Broader Neurochemical Framework

Increasingly, researchers argue that glutamate – the brain's primary excitatory neurotransmitter – may be the underlying driver of pathology in schizophrenia, with dopamine dysregulation being a downstream consequence rather than the root cause. The key evidence comes from studies of NMDA receptor antagonists:

• PCP (Phencyclidine) and Ketamine Studies: Both drugs block NMDA glutamate receptors and, when administered to healthy volunteers, produce a comprehensive model of schizophrenia symptoms – including both positive symptoms (hallucinations, paranoia) and, crucially, negative symptoms (blunted affect, social withdrawal) and cognitive symptoms (working memory impairment). This is significant because amphetamine-induced psychosis largely models only positive symptoms. The ability of NMDA antagonists to induce the full symptom profile of schizophrenia has led many researchers to conclude that NMDA receptor hypofunction is a more complete model.
• NMDA Hypofunction and Dopamine: One proposed mechanism is that NMDA receptor hypofunction on inhibitory interneurons (specifically GABAergic interneurons) in the prefrontal cortex leads to their disinhibition. This in turn leads to excessive glutamate release in the striatum, which drives the over-activation of the mesolimbic dopamine pathway and increases dopamine release. In this model, dopamine dysregulation is an intermediate step in a cascade that begins with NMDA receptor hypofunction.

Evaluation of the Glutamate Hypothesis:
• Strength: It is more comprehensive than the original dopamine hypothesis, accounting for the full range of positive, negative, and cognitive symptoms. It also provides a potential explanation for why purely dopamine-targeting antipsychotics are largely ineffective against negative symptoms.
• Limitation: It is very difficult to study the glutamate system directly in living humans. There are currently no effective glutamate-targeting treatments for schizophrenia in widespread clinical use, which limits the degree to which the hypothesis can be "treated to confirm" its validity.
• Integration: The most accurate current model of schizophrenia's neurochemistry is not "dopamine OR glutamate" but a complex, interacting system involving both, alongside serotonin, GABA, and other neuromodulators. This highlights the profound complexity of the disorder and the limitations of single-neurotransmitter explanations.

• Interactive Exercise (15 mins): Present students with two mini-cases: one with predominantly positive symptoms, one with predominantly negative symptoms. In an online poll, ask them which dopamine pathway is likely implicated in each case.
• Classroom Application (15 mins): In breakout rooms, have students create a short presentation slide explaining the dopamine hypothesis to a family member of a newly diagnosed patient in simple terms.

4. Distinction-Level Thinking

Analytical Question: ";Evaluate the claim that the dopamine hypothesis is a good example of the 'treatment aetiology fallacy' (the mistaken belief that the effectiveness of a treatment reveals the cause of the disorder)."

5. Useful Resources

• Article: Howes, O. D., & Kapur, S. (2009). The dopamine hypothesis of schizophrenia: version III—the final common pathway. Molecular psychiatry, 14(8), 761-773.
• Video: "The Dopamine Hypothesis Of Schizophrenia" - A clear visual explanation. Watch on YouTube

Session 7: Biological Explanations of Schizophrenia - Neural Correlates

Session Duration: 2 Hours (120 mins)

Teacher's Checklist

1. Structural Brain Abnormalities (40 mins)

Neural correlates are measurements of the structure or function of the brain that correlate with the symptoms of schizophrenia. Research using MRI has identified several structural differences.

• Enlarged Ventricles: This is one of the most consistent findings. Ventricles are fluid-filled cavities; their enlargement suggests a loss of surrounding brain tissue. This is particularly associated with negative symptoms.
• Reduced Grey Matter Volume: Many studies show reduced grey matter in the temporal and frontal lobes. This may link to auditory hallucinations (temporal lobe) and disorganised thought (frontal lobe).

2. Functional Brain Abnormalities (40 mins)

Functional imaging techniques like fMRI measure brain activity, revealing patterns of abnormal functioning.

• Hypofrontality: This refers to reduced activity in the frontal lobes, particularly when performing cognitive tasks. This is a strong neural correlate of the negative and cognitive symptoms.
• Abnormal Temporal Lobe Activity: Patients experiencing auditory hallucinations show increased activity in auditory processing areas (e.g., superior temporal gyrus), suggesting hallucinations may be a misattribution of inner speech to an external source.

3. Evaluation of Neural Correlates and Activities (40 mins)

Strengths:
• The evidence is extensive and often highly reliable, with findings like enlarged ventricles being replicated many times.
Limitations:
• The Correlation-Causation Problem: This is the most significant limitation. We do not know if the brain abnormalities cause schizophrenia or if they are an effect of the disorder or its treatment.
• Not All Patients Show Abnormalities: These findings are not universal, which weakens the argument that they are a primary cause.
• Heterogeneity: Different patients show different patterns of brain abnormality, suggesting schizophrenia is not a single disorder.

• Interactive Exercise (15 mins): Show students two anonymized brain scan images (one control, one with enlarged ventricles). In breakout rooms, they must label the key difference and write a short paragraph explaining why this is a 'correlate' and not necessarily a 'cause'.
• Classroom Application (15 mins): Pose the question for a class discussion: "If a brain scan could identify a 15-year-old as having a high-risk brain structure for schizophrenia, what are the ethical pros and cons of informing them and their family?"

4. Distinction-Level Thinking

Analytical Question: ";How does the evidence from neural correlates both support and challenge the revised dopamine hypothesis? (Hint: Consider the location of the mesocortical pathway)."

5. Useful Resources

• Article: van Erp, T. G., et al. (2016). Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls in 30 cohorts. Molecular psychiatry, 21(8), 1084-1090.
• Video: "Schizophrenia and Brain Structure" - A clear, animated overview. Watch on YouTube

Session 8: Psychological Explanations of Schizophrenia - Family Dysfunction

Session Duration: 2 Hours (120 mins)

Teacher's Checklist

1. Historical Theories of Family Dysfunction (40 mins)

A. The Schizophrenogenic Mother

This is a historical psychodynamic explanation (Fromm-Reichmann, 1948) suggesting that a cold, rejecting, and controlling mother could cause schizophrenia.
Evaluation: This theory is no longer accepted. It is based on subjective case studies and led to immense suffering by blaming parents (especially mothers) for their child's severe illness.

B. Double Bind Theory

Proposed by Bateson et al. (1956), this theory focuses on dysfunctional communication. A double bind is a ";no-win" situation where a child receives contradictory verbal and non-verbal messages from a parent.
Example: A mother tells her child "I love you" in a cold, rigid tone while pushing them away.
Evaluation: While it highlights the importance of communication, there is little solid evidence that double binds are more common in families with schizophrenia. It is also seen as a form of parent-blaming.

2. Expressed Emotion (EE) (20 mins)

This is a more modern and well-supported explanation. Expressed Emotion refers to a negative emotional climate within a family, characterized by:

• Criticism: Hostile comments about the patient's behaviour.
• Hostility: Rejection of the patient and anger towards them.
• Emotional Over-Involvement (EOI): Over-protective behaviour that smothers the patient.

Key Finding: EE is not seen as a cause of schizophrenia, but as a major factor in relapse. Patients returning from hospital to a high-EE family are about four times more likely to relapse. The high-stress environment acts as a trigger for those with a pre-existing vulnerability (linking to the diathesis-stress model).

The Research Evidence for Expressed Emotion

The empirical foundation for EE as a relapse predictor is robust. Vaughn and Leff (1976) conducted one of the most influential studies. They followed 128 patients with schizophrenia who had been discharged from hospital and assessed the level of EE in their family homes. Key findings included:

• In high-EE households, the relapse rate was 51% within nine months of discharge.
• In low-EE households, the relapse rate was only 13%.
• Two factors were found to moderate the effect of high EE: medication compliance and amount of face-to-face contact. Patients in high-EE households who spent fewer than 35 hours per week in contact with the high-EE family member had a relapse rate of 28%, compared to 69% for those spending more than 35 hours in contact. This suggests the impact of EE is partly a function of exposure.

Later research extended these findings cross-culturally. Studies comparing schizophrenia outcomes in the UK versus India found that patients in India had consistently better long-term outcomes despite less access to psychiatric services. One proposed explanation is that extended family structures in India may dilute the intensity of face-to-face contact with any single high-EE individual, reducing relapse risk. This cross-cultural evidence is important as it suggests social and family environments can be considered a modifiable risk factor.

Measuring EE: EE is typically assessed using the Camberwell Family Interview (CFI), a semi-structured interview conducted with each family member separately. Transcripts are coded for the frequency of critical comments, presence of hostility, and a global rating of EOI. The CFI takes 1–2 hours to administer and requires specialist training to score reliably, which is a practical limitation for widespread clinical use. Briefer tools such as the Family Questionnaire (FQ) and the Level of Expressed Emotion (LEE) scale have been developed as alternatives, though with some sacrifice of reliability.

3. Evaluation and Interactive Activities (60 mins)

Overall Evaluation:
• Parent-Blaming: The early theories are highly unethical. Modern approaches focus on supporting families, not blaming them.
• Diathesis-Stress: Family dysfunction is better understood as a significant environmental stressor in the diathesis-stress model.
• Practical Applications: The concept of EE has led to effective Family Therapy interventions aimed at reducing EE and lowering relapse rates.

• Interactive Exercise (20 mins): In breakout rooms, provide two short scripts of a family conversation. One script should be high in EE, the other low in EE. Groups must identify the specific examples of EE and rewrite the first script to be a low-EE conversation.
• Classroom Application (20 mins): Host a structured debate: "Psychological explanations for schizophrenia have done more harm than good." One side argues yes (citing parent-blaming), the other argues no (citing the development of therapies like Family Therapy).

4. Distinction-Level Thinking

Analytical Question: "How does the concept of Expressed Emotion successfully integrate psychological and biological explanations of schizophrenia via the diathesis-stress model?"

5. Useful Resources

• Article: Kavanagh, D. J. (1992). Recent developments in expressed emotion and schizophrenia. The British Journal of Psychiatry, 160(5), 601-620.
• Video: "Psychological Explanations for Schizophrenia: Family Dysfunction" - A clear overview for students. Watch on YouTube

Session 9: Psychological Explanations of Schizophrenia - Cognitive Explanations

Session Duration: 2 Hours (120 mins)

Teacher's Checklist

1. Cognitive Explanations of Schizophrenia (75 mins)

The cognitive approach focuses on dysfunctional thought processes as the key to understanding the symptoms of schizophrenia. The core idea is that the schizophrenic brain has deficits in information processing.

A. Frith's Cognitive Model (1992)

Chris Frith proposed two key cognitive deficits:

1. Deficits in Metarepresentation: This is the ability to reflect on our own thoughts and understand the mental states of others. A failure in this system can explain:
   • Delusions of Control / Thought Insertion: A failure to recognise that one's own thoughts are self-generated.
   • Auditory Hallucinations: A failure to recognise that one's own inner speech is self-generated, leading to it being perceived as an external voice.
2. Deficits in Central Control: This is the ability to suppress automatic responses and perform deliberate actions. A failure in this system can explain:
   • Disorganised Speech: The individual is unable to suppress automatic associations that come to mind when speaking, leading to derailment.

B. Attentional Biases

This refers to a tendency to pay more attention to threatening stimuli. In individuals with paranoia, this could mean they are hyper-vigilant to cues of threat, interpreting neutral events as hostile.

C. The Jumping to Conclusions (JTC) Bias

Research by Garety et al. (2001) and Bentall et al. (2001) identified a specific reasoning bias called the 'Jumping to Conclusions' (JTC) bias, which is particularly strongly associated with delusional thinking. People with delusions tend to reach firm conclusions on the basis of very limited evidence, without seeking further information to confirm or disconfirm their belief.

The JTC bias is elegantly demonstrated using the Beads Task (also called the 'Probabilistic Reasoning Task'). Two jars are shown, each containing coloured beads in different ratios. For example, Jar A has 85 red and 15 blue beads, and Jar B has 85 blue and 15 red beads. A jar is secretly selected and beads are drawn one at a time. The participant must decide which jar they think is being drawn from. Research shows that:

• Healthy participants typically wait for 4–5 beads before deciding.
• Patients with delusions typically decide after seeing only 1–2 beads, despite the very limited information available.
• This difference is highly reliable, replicated across many studies, and specifically associated with current delusional thinking rather than with a diagnosis of schizophrenia per se.

Evaluation of JTC: The JTC bias provides a specific, experimentally testable cognitive mechanism that can explain how delusional beliefs may be formed and then maintained despite contradictory evidence. This has direct clinical implications: CBTp specifically targets this reasoning bias through techniques that encourage patients to 'collect more evidence' before making a conclusion. However, JTC is a probabilistic finding: not all patients with delusions show it, and it is also found in people with anxiety disorders, suggesting it may be a broader thinking style rather than specific to schizophrenia.

D. Theory of Mind (ToM) Deficits

Theory of Mind (often called 'mentalising') is the ability to attribute mental states – beliefs, desires, intentions, and emotions – to other people and to understand that others have mental states different from one's own. This is closely linked to Frith's concept of metarepresentation.

Research using classic ToM tasks has consistently shown that people with schizophrenia perform worse than controls, particularly on tests requiring understanding of:

• First-Order False Belief: Understanding that another person can hold a belief that is factually false (e.g., the Sally-Anne test).
• Second-Order False Belief: Understanding what one person thinks another person thinks (e.g., 'Does Mary think that John knows where the ball is?'). This requires a more complex level of reasoning.
• Irony and Social Faux Pas: Understanding when someone has unintentionally said something socially inappropriate. People with schizophrenia often struggle to recognise these social violations.

Links to Specific Symptoms: ToM deficits may directly produce specific symptoms. Thought insertion and thought broadcast may result from a failure to attribute one's own mental states as self-generated ('this thought is mine'). Paranoia may arise when a person misattributes others' neutral or benign intentions as hostile, because the system that evaluates others' mental states is dysregulated. Importantly, ToM deficits persist even when acute psychotic symptoms are in remission, suggesting they may be a trait vulnerability rather than purely a state-dependent symptom.

2. Evaluation and Interactive Activities (45 mins)

Evaluation:
Strengths: The cognitive model provides a plausible explanation for the mechanisms behind specific symptoms and has led to the development of Cognitive Behavioural Therapy for psychosis (CBTp).
Limitations: It is more descriptive than explanatory. It explains the 'what' (what is happening in the mind) but not the 'why' (the ultimate cause of these deficits), which are likely rooted in neurochemical and genetic factors.

• Interactive Exercise (15 mins): The Stroop Test. Show students a list of colour names written in incongruent ink colours (e.g., the word "BLUE" written in red ink). Ask them to name the ink colour, not read the word. This demonstrates the concept of central control. Use an online version for an interactive experience.
• Classroom Application (15 mins): Present a short vignette of a patient describing their experience of thought insertion. In breakout rooms, students must explain this symptom using the concept of 'defective metarepresentation'.

3. Distinction-Level Thinking

Analytical Question: "Does the cognitive approach simply describe the symptoms of schizophrenia at a different level, or does it provide a true causal explanation? Justify your answer."

4. Useful Resources

• Article: Frith, C. D. (1992). *The cognitive neuropsychology of schizophrenia*. Psychology Press.
• Video: "Cognitive Explanations of Schizophrenia" by tutor2u. Watch on YouTube

Session 10: Therapies for Schizophrenia - Biological Treatments (Antipsychotics)

Session Duration: 2 Hours (120 mins)

Teacher's Checklist

1. Typical (First-Generation) Antipsychotics (40 mins)

Developed in the 1950s, these were the first effective drug treatments for schizophrenia.
Examples: Chlorpromazine, Haloperidol.
Mechanism of Action: They are strong dopamine antagonists. They work by blocking D2 dopamine receptors, particularly in the mesolimbic pathway. This reduces dopamine transmission and positive symptoms.
Side Effects: Due to their powerful dopamine blocking action, they can cause significant motor side effects (Extrapyramidal Symptoms), including:

• Parkinsonism: Tremors, rigidity, and slow movement.
• Tardive Dyskinesia (TD): A serious and often irreversible condition with involuntary movements of the face, tongue, and limbs.

2. Atypical (Second-Generation) Antipsychotics (40 mins)

Developed from the 1980s onwards, these are now the first-line treatment.
Examples: Clozapine, Risperidone, Olanzapine.
Mechanism of Action: They also block dopamine receptors but bind more loosely and also act on serotonin receptors. This dual action is thought to be why they are effective against both positive and negative symptoms.
Side Effects: They have a much lower risk of motor side effects. However, they are associated with a high risk of serious metabolic side effects, including:

• Significant weight gain.
• Type 2 diabetes.
• High cholesterol.

3. Evaluation of Antipsychotics and Activities (40 mins)

Effectiveness:
• There is a large body of evidence showing that antipsychotics are significantly more effective than placebo.
• Atypical antipsychotics are generally considered more effective for negative symptoms.
Limitations:
• Side Effects & Adherence: The severe side effects are a major reason why many patients stop taking their medication, leading to relapse.
• Not a Cure: Antipsychotics manage symptoms but do not cure schizophrenia.

The CATIE Trial: Real-World Effectiveness Evidence

The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study (Lieberman et al., 2005) was a pivotal, large-scale, real-world trial funded by the US National Institute of Mental Health. It randomised 1,493 patients with chronic schizophrenia to one of five antipsychotics — both typical (perphenazine) and atypical (olanzapine, quetiapine, risperidone, ziprasidone) — and followed them for up to 18 months. The primary outcome measure was discontinuation of treatment, a composite measure combining both effectiveness and tolerability. Key CATIE findings:

• The Adherence Crisis: Approximately 74% of all patients discontinued their assigned medication before 18 months, regardless of which antipsychotic they were assigned. This dramatically highlighted the real-world scale of treatment non-adherence in schizophrenia.
• Olanzapine's Double-Edged Performance: Olanzapine (an atypical) had the lowest discontinuation rate (64%) and thus the best effectiveness profile. However, this came at the cost of highly significant metabolic side effects, including an average weight gain of 2 lbs per month.
• Typical Antipsychotic Performance: The typical antipsychotic perphenazine performed comparably to most atypicals, with no statistically significant difference in discontinuation rates. This challenged the commonly held assumption that atypicals are clearly and universally superior to typicals.

Clinical Implications of CATIE: The trial shifted prescribing guidance towards a more individualised, patient-centred approach. Rather than recommending a single 'best' drug class, NICE guidelines now emphasise shared decision-making, where the clinician and patient discuss side-effect profiles in the context of the individual's health priorities, lifestyle, and preferences.

Long-Acting Injectable (LAI) Antipsychotics

A key practical challenge in schizophrenia management is medication non-adherence, which, as CATIE demonstrated, is the rule rather than the exception. Long-Acting Injectable (LAI) formulations (historically called 'depot' antipsychotics) are injected every 2–4 weeks or even every 1–3 months, eliminating the need for daily oral dosing.

• Advantages: Reliable, predictable blood plasma levels; clinicians can confirm adherence at each injection appointment; some studies suggest lower relapse rates compared to oral antipsychotics in routine clinical practice; regular contact with the healthcare team at injection visits has psychosocial benefits.
• Disadvantages: The process can feel coercive and may undermine patient autonomy; side effects cannot be rapidly managed by simply stopping the injection as they can with oral medication; injection site discomfort and reactions.
• Evaluation: Despite their theoretical advantages, a 2012 Cochrane review found mixed evidence for superiority of LAIs over oral antipsychotics in randomised controlled trials, though observational 'mirror-image' studies using patients as their own controls tended to show clearer benefits. This discrepancy is thought to reflect the artificially high adherence rates in clinical trials, which do not reflect real-world practice.

Treatment-Resistant Schizophrenia and Clozapine

Approximately 20–30% of patients with schizophrenia have treatment-resistant schizophrenia (TRS), defined as a failure to achieve adequate symptom control after at least two adequately dosed trials of different antipsychotics. For this population, clozapine (Clozaril) is the evidence-based treatment of choice. Clozapine produces clinically meaningful reductions in symptoms in approximately 30–60% of TRS patients who have failed other medications.

Its mechanism differs from other antipsychotics: clozapine has relatively weak D2 blockade but acts on a broad range of receptor types (5-HT2A, muscarinic, histamine H1, and others). The critical limitation is its risk of agranulocytosis (~1–2% of patients) — a dangerous reduction in white blood cells that can be fatal if untreated. All patients on clozapine are enrolled in a mandatory blood monitoring scheme, with weekly counts for the first 18 weeks, then fortnightly. This illustrates a core principle in healthcare: a clinically significant treatment with a rare but serious risk can be managed through systematic monitoring.

• Interactive Exercise (15 mins): Create a simple table in a shared online document with two columns: "Typical Antipsychotics" and "Atypical Antipsychotics." Students must work in groups to fill in the mechanism, target symptoms, and key side effects for each.
• Classroom Application (15 mins): Host a role-play. One student plays a clinician, the other a patient hesitant to take medication. The "clinician" must explain the risks and benefits of an atypical antipsychotic.

4. Distinction-Level Thinking

Analytical Question: "Considering the different side-effect profiles, conduct a cost-benefit analysis for a young, newly diagnosed patient being prescribed a typical versus an atypical antipsychotic. Justify your conclusion."

5. Useful Resources

• Article: Leucht, S., et al. (2013). Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. The Lancet, 382(9896), 951-962.
• Video: "Pharmacology of Antipsychotics" by Speed Pharmacology. Watch on YouTube

Session 11: Therapies for Schizophrenia - ECT & Ethical Issues

Session Duration: 2 Hours (120 mins)

Teacher's Checklist

1. Electroconvulsive Therapy (ECT) (30 mins)

ECT involves passing a controlled electric current through the brain to induce a brief seizure. It is always administered under general anaesthetic and with muscle relaxants.
Use in Schizophrenia: ECT is not a first-line treatment. It may be considered in specific situations, such as:

• Catatonic Schizophrenia: It can be highly effective for the motor symptoms of catatonia.
• When a rapid response is needed and medication is not working.

Mechanism: The exact mechanism is not fully understood, but it is thought to affect neurotransmitter levels and neuroplasticity.
Side Effects: The main side effect is memory loss, which is a major reason for its controversial status.

2. Major Ethical Issues in Treatment (60 mins)

The treatment of severe mental illness like schizophrenia raises profound ethical questions.

• Informed Consent: For consent to be valid, a person must have the capacity to understand the information. A key symptom of schizophrenia can be anosognosia (a lack of insight into one';s own illness). If a person does not believe they are ill, can they truly give informed consent for treatment?
• Coercive Treatment (Involuntary Commitment): Most mental health legislation allows for a person to be detained and treated against their will if they are deemed a risk to themselves or others. This pits the ethical principle of autonomy (the right to self-determination) against the principle of beneficence (the duty to act in the person's best interest).
• The Humanistic Critique: Figures like Thomas Szasz have argued that the medical model pathologizes human experience and that treatments like medication are tools of social control, enforcing conformity rather than promoting well-being.

3. Interactive & Application Activities (30 mins)

• Interactive Exercise (15 mins): Present a case: "A 22-year-old man with schizophrenia is refusing medication. He is not eating, believes his food is poisoned, and his family is terrified he will harm himself." In breakout rooms, students must discuss the ethical arguments for and against treating him against his will, referencing autonomy and beneficence.
• Classroom Application (15 mins): Host a formal debate on the motion: "Involuntary treatment for schizophrenia is a necessary and ethical practice."

4. Distinction-Level Thinking

Analytical Question: "How do the ethical challenges associated with treating schizophrenia (e.g., issues of consent and capacity) undermine the simple application of a purely biological model of the disorder?"

5. Useful Resources

• Article: Szasz, T. S. (1960). The myth of mental illness. American Psychologist, 15(2), 113–118. (The classic anti-psychiatry text).
• Video: "Mental Health and Human Rights" by the World Health Organization. Watch on YouTube

Session 12: Therapies for Schizophrenia - Psychological Treatments (CBTp)

Session Duration: 2 Hours (120 mins)

Teacher's Checklist

1. Introduction to Cognitive Behavioural Therapy for psychosis (CBTp) & Process (75 mins)

CBTp is a psychological therapy based on the idea that our thoughts (cognitions) influence our feelings and behaviours. It does not aim to eliminate symptoms like hallucinations. Instead, it aims to change the way patients think about and respond to their psychotic experiences, reducing distress and improving functioning.
Example Case: A patient believes they are being monitored by MI5 (delusion) and hears voices telling them they are worthless (hallucination).

1. Assessment & Engagement: The therapist builds a trusting relationship.
2. Formulation: The therapist and patient work together to create a shared understanding ('map') of how the problems developed.
3. Intervention - Challenging Beliefs: The therapist does not tell the patient their beliefs are wrong. Instead, they use techniques to help the patient question their own beliefs:
   • Normalization: "Many people have unusual experiences like hearing voices when they are under extreme stress."
   • Reality Testing: The therapist and patient collaboratively design 'experiments' to test the belief. For the MI5 delusion, they might agree to check the patient's flat for bugs. When none are found, this provides evidence against the belief.
4. Intervention - Managing Symptoms: The therapist teaches coping strategies. For the voice saying "you're worthless," the patient might learn to challenge it ("That's just my illness talking") or use distraction techniques.

2. Evaluation and Interactive Activities (45 mins)

Evaluation:
Strengths: NICE (National Institute for Health and Care Excellence) recommends CBTp for all people with schizophrenia. Studies show it is effective in reducing positive symptoms and lowering relapse rates. It gives patients agency and coping skills.
Limitations: It is not a cure. It requires trained therapists and can be expensive. Some patients may struggle to engage with the therapy.

• Interactive Exercise (20 mins): Provide students with a delusional belief (e.g., "My thoughts are being broadcast on the radio"). In breakout rooms, they must brainstorm two 'reality testing' experiments a therapist could conduct.
• Classroom Application (15 mins): In pairs, students role-play a short CBTp session. One student is the patient describing a hallucination, and the other is the therapist practicing 'normalization'.

3. Distinction-Level Thinking

Analytical Question: ";CBTp does not aim to eliminate psychotic symptoms but to help patients live with them. Evaluate the implications of this goal compared to the biological approach, which aims for symptom reduction."

4. Useful Resources

• Article: Turkington, D., & Siddle, R. (2009). Cognitive behaviour therapy for schizophrenia. Advances in Psychiatric Treatment, 6(3), 189-197.
• Video: "Cognitive Behavioral Therapy for Psychosis (CBTp)" by the Beck Institute. Watch on YouTube

Session 13: Therapies for Schizophrenia - Other Psychological & Social Treatments

Session Duration: 2 Hours (120 mins)

Teacher's Checklist

1. Family Therapy (40 mins)

Theoretical Basis: This therapy is directly linked to the concept of Expressed Emotion (EE). The primary goal is to reduce the negative emotional climate within a family to lower the patient's risk of relapse.
Process: It involves the patient and their family meeting with a therapist. Key components include:

• Psychoeducation: Providing the family with information about schizophrenia.
• Improving Communication: Teaching the family to communicate in a more positive and less critical way.
• Problem-Solving Skills: Helping the family develop strategies for coping with stress.

Evaluation: Family therapy is strongly recommended by NICE. Research shows it is effective in reducing relapse rates and improving medication adherence.

2. Token Economies (40 mins)

Theoretical Basis: This is a behavioural therapy based on operant conditioning, designed to manage negative symptoms in long-stay hospital settings.
Process: Desirable behaviours (e.g., personal hygiene) are identified. When a patient performs one of these behaviours, they are rewarded with a token (a secondary reinforcer). Tokens can then be exchanged for rewards (primary reinforcers), such as sweets or a movie night.
Evaluation: Token economies can be effective within an institutional setting. However, the positive behaviours often do not generalize to the outside world. There are also ethical concerns that it is dehumanizing.

3. Psychoanalysis (40 mins)

Theoretical Basis: This is the original "talk therapy" developed by Freud. It is not a modern treatment for schizophrenia.
Process: The goal is to uncover unconscious conflicts from childhood that are believed to be the cause of the disorder.
Evaluation: There is no evidence that psychoanalysis is an effective treatment for schizophrenia. For someone in acute psychosis, it could be distressing and harmful. It is important to understand it from a historical perspective as a contrast to modern, evidence-based therapies.

• Interactive Exercise (15 mins): In breakout rooms, assign each group one of the three therapies. They must create a "sales pitch" for their therapy, outlining its main goal and process.
• Classroom Application (15 mins): Present a case of a patient with prominent negative symptoms. Have the class discuss which of the three therapies would be most and least appropriate and why.

4. Distinction-Level Thinking

Analytical Question: "Compare and contrast the theoretical underpinnings of CBTp and Family Therapy for schizophrenia. How do their different assumptions about the 'problem' lead to different therapeutic goals?"

5. Useful Resources

• Article: Pharoah, F., Mari, J., Rathbone, J., & Wong, W. (2010). Family intervention for schizophrenia. Cochrane database of systematic reviews, (12).
• Video: "Token Economy" - A simple explanation of the behavioural principle. Watch on YouTube

Session 14: The Role of the Clinical Psychologist

Session Duration: 2 Hours (120 mins)

Teacher's Checklist

1. The Discipline of Clinical Psychology (30 mins)

Clinical psychology is a branch of psychology concerned with the assessment and treatment of mental illness and abnormal behaviour. It integrates the science of psychology with the treatment of complex human problems. It is distinct from psychiatry, which is a branch of medicine. While psychiatrists can prescribe medication, the primary tools of a clinical psychologist are psychological assessment and psychotherapy.

2. The Core Roles of a Clinical Psychologist (45 mins)

The work of a clinical psychologist can be summarized by the "four Ds": Describe, Explain, Predict, and Change behaviour. This translates into several key professional roles.
Case Example: A patient with schizophrenia.

1. Assessment: The psychologist gathers information to understand the patient's problems through clinical interviews, psychometric testing, and observation.
2. Formulation: This is a key skill. It involves creating a hypothesis or "story" about the origins and maintaining factors of a patient's problems, drawing on psychological theory. Example Formulation: "It seems that a genetic vulnerability combined with the stress of leaving home for university triggered your initial psychotic experiences. Your way of making sense of these was to believe you were being monitored, which made you withdraw from others."
3. Intervention: Based on the formulation, the psychologist delivers a psychological therapy (e.g., CBTp).
4. Evaluation: The psychologist systematically monitors the patient's progress to see if the intervention is working.

3. The Scientist-Practitioner Model & Activities (45 mins)

Clinical psychologists are trained as scientist-practitioners. This means their clinical practice is grounded in scientific evidence, and they have the skills to conduct research to evaluate their practice. In modern healthcare, they work in a multidisciplinary team (MDT) alongside psychiatrists, nurses, and social workers.

The 5P Formulation Model

One of the most widely-used frameworks for psychological formulation is the 5Ps Model, which provides a structured way to understand the factors contributing to a person's difficulties. This model is taught in clinical psychology training programmes and widely used in the NHS. The five components are:

• Presenting Problem: What is the patient experiencing? What are the specific symptoms and difficulties they bring to therapy? (e.g., 'I hear voices that tell me I am worthless and I have stopped going out.')
• Predisposing Factors: What historical or background factors made this person vulnerable to developing this problem? This includes genetic vulnerability (family history), early adverse experiences (childhood trauma, attachment difficulties), personality characteristics, and developmental factors.
• Precipitating Factors: What specific events or circumstances triggered the current episode? These are the 'stressors' in the diathesis-stress model. For schizophrenia, this might be leaving home, bereavement, substance misuse, or a major life change.
• Perpetuating Factors: What is maintaining the problem now? These are the factors that keep the person stuck – e.g., social isolation, medication non-adherence, high expressed emotion at home, unhelpful coping behaviours (e.g., substance use to manage voices), and negative beliefs about the illness.
• Protective Factors: What are this person's strengths and resources? These are factors that will support recovery – e.g., a supportive partner, good insight into their condition, motivation to engage with therapy, employment, and spiritual beliefs.

Example Formulation for a Patient with Schizophrenia: 'Alex is a 24-year-old man who presents with command hallucinations and persecutory delusions (Presenting). He has a first-degree relative with schizophrenia and experienced emotional neglect in childhood (Predisposing). His symptoms began when he started university and began using cannabis heavily (Precipitating). He has largely stopped taking his medication because he believes it "changes who he is," and his family are very critical of his illness (Perpetuating). He has strong artistic talent, a supportive college tutor, and expresses a desire to return to his studies (Protective).'

The 5P formulation guides intervention: the clinician targets the perpetuating factors most amenable to change (e.g., medication beliefs via CBTp, family EE via Family Therapy), while building on protective factors. This contrasts with the medical model's diagnosis-first approach, which may lead straight to medication without context.

Professional Boundaries and the BPS Competency Framework

In the UK, clinical psychology is regulated by the Health and Care Professions Council (HCPC), which sets the minimum standards for safe and effective practice. Practitioner psychologists must also adhere to the code of conduct of the British Psychological Society (BPS). Key professional boundaries and standards include:

• Competence: Practitioners should only work within their areas of training and competence. A clinical psychologist trained in CBT should not deliver a therapy they have not been trained in (e.g., schema therapy) without appropriate supervision and training.
• Confidentiality and Duty to Disclose: Information shared within therapy is confidential, with specific exceptions (e.g., if the patient discloses an intention to harm themselves or others, or if a child is at risk). Navigating these boundaries requires careful judgment.
• Distinguishing Roles in the MDT: Clinical psychologists differ from psychiatrists (medical doctors who can prescribe medication and section patients under the Mental Health Act), counsellors (who undergo shorter training, typically working with less complex presentations), and psychotherapists (who may have different theoretical training, e.g., psychodynamic). The clinical psychologist's distinctive contribution is psychological assessment, formulation, and evidence-based psychological therapy for complex difficulties.

• Interactive Exercise (15 mins): In breakout rooms, give students a mini-case (e.g., a patient with schizophrenia and co-morbid depression). They must list the different professionals who might be in the MDT and describe the specific role each would play.
• Classroom Application (20 mins): Provide a simplified case formulation. Students must work in pairs to identify which psychological theory (e.g., cognitive, behavioural) is being used and suggest an appropriate intervention.

4. Distinction-Level Thinking

Analytical Question: "Analyse the strengths and limitations of the scientist-practitioner model in everyday clinical practice. Does the 'scientist' role ever conflict with the 'practitioner' role?"

5. Useful Resources

• Article: Routh, D. K. (2000). Clinical psychology training: A history of ideas and practices. Applied and Preventive Psychology, 9(4), 237-247.
• Video: "What is a Clinical Psychologist?" by the British Psychological Society. Watch on YouTube

Session 15: Depression - Clinical Characteristics and Classification

Session Duration: 2 Hours (120 mins)

Teacher's Checklist

1. Distinguishing Clinical Depression from Sadness (30 mins)

It is vital to distinguish between the normal human emotion of sadness and the clinical syndrome of depression. Sadness is a temporary and proportionate response to a negative event. Major Depressive Disorder (MDD), or clinical depression, is a mood disorder characterized by a persistent low mood and/or a loss of interest or pleasure (anhedonia) that is severe, long-lasting (at least two weeks), and impairs functioning.

2. Clinical Characteristics of MDD (60 mins)

According to the DSM-5, a diagnosis of MDD requires at least five symptoms to be present for at least two weeks, with at least one being depressed mood or anhedonia. The symptoms can be grouped as follows:

• Affective (Emotional) Symptoms: Persistent depressed mood, anhedonia, feelings of worthlessness or excessive guilt.
• Behavioural Symptoms: Psychomotor agitation or retardation, social withdrawal, changes in activity levels.
• Cognitive Symptoms: Diminished concentration, indecisiveness, recurrent thoughts of death or suicide.
• Somatic (Physical) Symptoms: Significant weight change, insomnia or hypersomnia, fatigue or loss of energy.

3. Issues in Diagnosis & Activities (30 mins)

Reliability: Generally considered good, as the criteria are well-defined.
Validity:
• Symptom Overlap: Many symptoms (e.g., fatigue) are common in other illnesses.
• Cultural Differences: The presentation of depression varies. In some cultures, somatisation (expressing distress through physical symptoms) is more common.
• Heterogeneity: Two people can be diagnosed with MDD but share only one symptom, suggesting it is a very heterogeneous disorder.

Beyond MDD: A Spectrum of Depressive Disorders

Major Depressive Disorder is the most clinically significant diagnosis within a broader family of depressive disorders. An accurate understanding requires knowledge of related conditions:

• Persistent Depressive Disorder (PDD) / Dysthymia (ICD-10): Characterised by a chronically depressed mood lasting at least two years (one year in children/adolescents), with fewer and less severe symptoms than MDD. Patients describe a pervasive low mood as their 'normal.' Because the symptoms are chronic and less acute, many patients with PDD are undiagnosed or untreated for years. When MDD occurs on top of PDD ('double depression'), outcomes tend to be poorer.
• Seasonal Affective Disorder (SAD): A subtype of MDD with a seasonal pattern, typically with onset in autumn/winter and full remission in spring. SAD is thought to be related to reduced light exposure affecting melatonin and serotonin regulation. A key biological treatment is light therapy (bright light exposure for 20–60 minutes each morning), which has strong evidence of efficacy comparable to antidepressants for this specific presentation.
• Premenstrual Dysphoric Disorder (PMDD): A severe form of premenstrual syndrome characterised by significant mood disturbance (marked irritability, depression, anxiety) in the luteal phase of the menstrual cycle, resolving shortly after onset of menstruation. It is recognised in DSM-5 and is distinct from normal PMS. PMDD involves dysregulation in the serotonin system's response to hormonal fluctuations.
• Distinguishing MDD from Bipolar Disorder: This is a critical clinical distinction with major treatment implications. Bipolar disorder involves episodes of both depression and mania (or hypomania). A depressive episode in bipolar disorder is clinically indistinguishable from MDD — the differential diagnosis depends on correctly identifying previous hypomanic or manic episodes. Why it matters: Treating bipolar depression with an antidepressant alone (without a mood stabiliser) can trigger a manic episode. Studies suggest that 20–40% of patients initially diagnosed with MDD are eventually reclassified as having bipolar disorder, highlighting the importance of careful longitudinal assessment.

• Interactive Exercise (15 mins): Use an online quiz tool to present students with a list of symptoms. They must classify each symptom as Affective, Behavioural, Cognitive, or Somatic.
• Classroom Application (15 mins): Provide a case study of a patient presenting with fatigue, weight loss, and headaches. In breakout rooms, students must discuss the challenges of making a differential diagnosis.

4. Distinction-Level Thinking

Analytical Question: "Given the significant heterogeneity within the diagnosis of MDD, evaluate whether it is more of a useful 'syndrome' for guiding treatment than a single, valid disease entity."

5. Useful Resources

• Article: World Health Organization. (1992). *The ICD-10 classification of mental and behavioural disorders*. Read ICD-10 Criteria here
• Video: "What is depression?" by Helen M. Farrell (TED-Ed). Watch on YouTube

Session 16: Explanations of Depression - Biological and Psychological Approaches

Session Duration: 2 Hours (120 mins)

Teacher's Checklist

1. Biological Explanations of Depression (45 mins)

• Genetics: Depression runs in families. Twin studies show higher concordance rates for MDD in MZ twins (~30-40%) than DZ twins (~10-15%), suggesting a moderate genetic vulnerability.
• Neurochemistry - The Monoamine Hypothesis: This theory suggests depression is caused by low levels of monoamines, particularly serotonin.
  Evidence: The theory arose from the observation that antidepressants like SSRIs (Selective Serotonin Reuptake Inhibitors) work by increasing the availability of serotonin in the synapse.
  Evaluation: This is an oversimplified explanation. Antidepressants take weeks to work, even though they change serotonin levels immediately. It's now thought that serotonin is part of a more complex picture.

2. Psychological Explanations of Depression (45 mins)

• Beck's Cognitive Theory (1967): Proposes that depression is caused by negative thinking patterns.
  • Negative Schemas: Negative beliefs about the world, developed in childhood (e.g., "I am unlovable").
  • Cognitive Biases: Errors in logic, such as overgeneralisation ("I failed one test, so I'm a total failure").
  • The Negative Cognitive Triad: A cycle of negative automatic thoughts about the self, the world, and the future.
• Ellis's ABC Model (1962):
  • A - Activating Event: An event occurs (e.g., you are fired).
  • B - Beliefs: You interpret the event. An irrational belief might be "I am useless."
  • C - Consequences: The irrational belief leads to unhealthy emotional consequences (depression).

C. Seligman's Learned Helplessness Model

Martin Seligman (1974, 1975) proposed the learned helplessness model of depression, initially based on animal research. In his original experiments, dogs were subjected to inescapable electric shocks. When later given an opportunity to escape, the dogs failed to try \u2014 they had learned that their behaviour had no effect on the outcome, a state of learned helplessness. Seligman proposed a parallel in human depression: people who repeatedly experience uncontrollable negative events may come to believe their behaviour cannot improve their situation, leading to characteristic deficits:

• Motivational Deficit: Reduced initiative and the passive, withdrawn quality of depression.
• Cognitive Deficit: Difficulty learning that outcomes can be controlled, even when evidence suggests they can.
• Emotional Deficit: Persistent low mood and anhedonia.

Abramson, Seligman and Teasdale (1978) revised the model with the concept of depressogenic attributional style. They argued it is not the adverse event itself but how a person explains it that determines vulnerability to depression. A depressogenic style involves attributing bad events to causes that are:

• Internal: "I failed because I am stupid" (vs. external: "The exam was unfair").
• Stable: "I will always be this bad at things" (vs. unstable: "I had a bad day").
• Global: "This means I fail at everything" (vs. specific: "I find this topic hard").

Evaluation: The learned helplessness model has strong experimental support. The Attributional Style Questionnaire (ASQ) provides a reliable measurement tool with strong predictive validity for depression onset. However, the original animal experiments raise significant ethical concerns. The model is also criticised for being partly circular: asking someone who is already depressed about their attributional style gives results consistent with the theory, but this does not prove the attributional style preceded the depression. Modern research using prospective designs has provided stronger support, showing that a depressogenic style in non-depressed individuals predicts later depression when adverse events occur.

D. Evolutionary and Psychodynamic Perspectives

Social Competition Hypothesis (Price et al., 1994): From an evolutionary perspective, depression may have had adaptive value as an involuntary yielding strategy. In species with social hierarchies, individuals who lose competitions need to communicate submission to prevent further attack. Behaviours resembling depression \u2014 reduced eye contact, slumped posture, reduced activity, withdrawal \u2014 are effective submission signals. Depression may thus be an evolved mechanism that becomes activated when a person perceives themselves as losing a social competition, signalling "I give up" to others and to themselves. The modern context (workplace stress, social media comparisons, academic pressures) may over-activate this ancient system.

Evaluation: This hypothesis is theoretically coherent but largely speculative. It is difficult to falsify empirically. It also has potentially damaging implications (suggesting depression is a "submission" response) if communicated insensitively. Nevertheless, it highlights how social rank and social comparison processes \u2014 which are amenable to psychological intervention \u2014 are key triggers for depression in vulnerable individuals.

Psychodynamic Perspective: Freud (1917) proposed that depression results from incomplete grief. When a significant love object (a person or an ideal) is lost, instead of working through grief, the ego identifies with the lost object and internalises the ambivalence about it. Unconscious anger towards the lost object is redirected towards the self, experienced as self-hatred, worthlessness, and guilt. While this classical account lacks strong empirical support, it anticipates modern attachment theory findings \u2014 that insecure early attachment and unresolved losses are significant risk factors for adult depression \u2014 and connects to the interpersonal focus of IPT (covered in Session 17).

3. Evaluation and Interactive Activities (30 mins)

Evaluation: Cognitive models have strong supporting evidence and have led to the highly effective therapy of CBT. However, they are criticized for the chicken-and-egg problem: do negative thoughts cause depression, or does depression cause negative thoughts? The best explanation is an integrated one, like the diathesis-stress model.

• Interactive Exercise (15 mins): Provide students with a list of negative automatic thoughts (e.g., "Everyone thinks I'm boring"). In breakout rooms, they must identify which cognitive bias (e.g., mind-reading) is at play.
• Classroom Application (15 mins): Using Ellis's ABC model, give students an 'Activating Event' (e.g., "You get a poor grade"). They must write down a 'Rational Belief' and an 'Irrational Belief' and the different emotional 'Consequences'.

4. Distinction-Level Thinking

Analytical Question: "How can the cognitive and biological explanations for depression be integrated within a diathesis-stress framework to provide a more complete picture of the disorder?"

5. Useful Resources

• Article: Beck, A. T. (2008). The evolution of the cognitive model of depression and its neurobiological correlates. American journal of psychiatry, 165(8), 969-977.
• Video: "Explaining Depression | Cognitive Approach" by tutor2u. Watch on YouTube

Session 17: Therapies for Depression - Biological and Psychological Treatments

Session Duration: 2 Hours (120 mins)

Teacher's Checklist

1. Biological Therapies for Depression (45 mins)

• Antidepressants: These are the most common treatment.
  • SSRIs (Selective Serotonin Reuptake Inhibitors): Examples include Fluoxetine (Prozac). They are the first-line medical treatment and work by blocking the reuptake of serotonin, increasing its availability.
  • Tricyclics: An older class of antidepressant. They are also effective but have more severe side effects.
  Evaluation: Antidepressants are effective for many, particularly those with moderate to severe depression. However, they can take 4-6 weeks to work and have side effects.
• Electroconvulsive Therapy (ECT): As discussed previously, ECT is a highly effective treatment for severe, life-threatening, or treatment-resistant depression.

2. Psychological Therapies - Cognitive Behavioural Therapy (CBT) (45 mins)

CBT is the leading psychological treatment for depression. It is based on Beck';s and Ellis's cognitive models.
Process:

1. Identifying Negative Automatic Thoughts (NATs): The patient learns to identify negative thoughts (e.g., "I'm going to fail this presentation").
2. Challenging NATs: The therapist teaches the patient to challenge these thoughts by examining the evidence. "What's the evidence that you will fail? What's a more balanced thought?"
3. Behavioural Activation: A crucial component. The therapist and patient schedule positive and rewarding activities back into the patient's life to break the cycle of inactivity and low mood.

Evaluation: CBT is as effective as medication for mild to moderate depression and has a lower relapse rate, as it teaches lifelong skills. It is often used in combination with medication for severe depression.

3. Interpersonal Therapy (IPT)

Interpersonal Therapy (IPT) is a structured, time-limited psychological therapy (typically 12–16 sessions) that focuses on the interpersonal context of depression. Developed by Klerman and Weissman in the 1970s, IPT is based on the observation that depression is closely linked to difficulties in personal relationships and social roles. The key therapeutic idea is: even if interpersonal problems did not cause the depression, resolving them will alleviate it.

IPT focuses on one or two of four main problem areas:

• Grief: Complicated grief following bereavement; helping the patient to mourn and reconnect with others.
• Interpersonal Role Disputes: Conflicts with a significant other (partner, family member, colleague) about expectations and roles.
• Role Transitions: Difficulties adjusting to a major life change (e.g., divorce, retirement, becoming a parent, job loss).
• Interpersonal Deficits: Persistent difficulties in forming and maintaining relationships, often associated with a history of insecure attachment.

Evaluation of IPT: NICE recommends IPT as an alternative to CBT for depression. Meta-analyses show efficacy comparable to CBT and antidepressants for moderate depression. IPT may be particularly effective for patients whose depression is clearly interpersonally triggered (e.g., bereavement, relationship breakdown). It is less appropriate for patients with severe depression or significant cognitive impairment who may struggle with the interpersonal focus. A strength of IPT is its specific, teachable techniques, which make therapist training relatively straightforward and treatment delivery reliable.

4. Mindfulness-Based Cognitive Therapy (MBCT)

Mindfulness-Based Cognitive Therapy (MBCT), developed by Segal, Williams and Teasdale (2002), was specifically designed to prevent relapse in people who have had three or more episodes of depression. It integrates the cognitive therapy techniques of Beck with mindfulness-based stress reduction (MBSR) developed by Jon Kabat-Zinn.

The key insight of MBCT is that people who have been depressed before are particularly vulnerable to relapse because slight drops in mood can automatically reactivate the old patterns of negative thinking (the negative schemas of Beck's model). This 'ruminative' mode of mind — 'Why do I feel this way? What's wrong with me? When will I feel better?' — paradoxically deepens and prolongs the low mood.

MBCT teaches participants to recognise when they are entering this ruminative mode and to disengage from it by bringing attention to the present moment with an attitude of non-judgmental observation — 'mindfulness.' Rather than trying to suppress thoughts or feel differently, participants learn to observe their thoughts as 'just thoughts' and step back from them.

Evaluation of MBCT: This is the most evidence-based use of mindfulness in mental health. Multiple RCTs have shown that MBCT reduces the risk of depressive relapse by approximately 43% in patients with three or more previous episodes, compared to treatment as usual (Piet and Hougaard, 2011, meta-analysis). NICE recommends MBCT as a relapse-prevention therapy for this population. A limitation is that MBCT requires a period of relative stability — it is not appropriate during an acute depressive episode, as patients lack the attentional capacity to engage with mindfulness practice. It is most effective for people who show a specific pattern of 'discrepancy-based processing' (comparing how things are with how they should be), which is a stronger predictor of response than simply the number of previous episodes.

3. Evaluation and Interactive Activities (30 mins)

• Interactive Exercise (10 mins): Provide a short vignette of a depressed patient's thoughts. In a shared document, students must write a 'CBT-style' challenge to the negative thought.
• Classroom Application (20 mins): Host a debate: "Medication vs. Therapy: Which is the 'best' first-line treatment for moderate depression?" Students must use evidence on effectiveness, side effects, cost, and relapse rates.

4. Distinction-Level Thinking

Analytical Question: ";Evaluate the use of a 'combined treatment' approach (medication and CBT) for severe depression. Why might this be more effective than either treatment alone?"

5. Useful Resources

• Article: Hollon, S. D., Thase, M. E., & Markowitz, J. C. (2002). Treatment and prevention of depression. Psychological Science in the Public Interest, 3(2), 39-77.
• Video: "Depression: explaining and treating (cognitive approach)" by tutor2u. Watch on YouTube

Session 18: Evaluating Therapies for Depression & Public Health Approaches

Session Duration: 2 Hours (120 mins)

Teacher's Checklist

1. Analysing the Effectiveness of Therapies for Depression (45 mins)

When evaluating therapies, we need to ask "For whom does it work, and under what circumstances?".
Key Considerations:

• Severity of Depression: For mild depression, therapies like exercise can be effective. For severe depression, combined treatment (medication + therapy) is often best.
• The Treatment-Aetiology Fallacy: This is a critical evaluation point. It is the logical error of assuming that the effectiveness of a treatment reveals the cause of the disorder. Example: Aspirin cures a headache, but that doesn't mean the headache was caused by a lack of aspirin. Similarly, the fact that SSRIs can treat depression does not prove that depression is caused by a lack of serotonin.
• Relapse Prevention: A key measure of long-term effectiveness. Psychological therapies like CBT often have an advantage here because they equip patients with lifelong coping skills.

2. Public Health Approaches to Mental Health (30 mins)

A public health approach focuses on the entire population, with the goal of preventing mental illness and promoting mental wellbeing. This involves moving beyond a purely medical model to consider social and environmental factors.
Key Strategies:

• Reducing Stigma: Public awareness campaigns that encourage people to talk about mental health.
• Improving Social Networks: Tackling loneliness and promoting community engagement.
• Addressing Social Inequality: Recognizing that factors like poverty and discrimination are major risk factors.
• Promoting Happiness and Wellbeing: Initiatives in schools and workplaces that teach skills like mindfulness and resilience.

Evidence-Based Public Health Interventions: A Closer Look

Several specific public health interventions have accumulated meaningful evidence of effectiveness:

• Exercise as a Public Health Strategy: Blumenthal et al. (1999) demonstrated that 30 minutes of aerobic exercise three times per week was as effective as an SSRI (sertraline) for moderate depression in older adults after 16 weeks. The relapse rate at 10-month follow-up was significantly lower in the exercise group. Exercise is now recommended by NICE as a first-line treatment for mild-to-moderate depression. The proposed mechanisms include: increased serotonin and endorphin release; reduced HPA axis activity (thereby reducing cortisol, the stress hormone); increased neurogenesis in the hippocampus (which is found to be reduced in depression); and the psychosocial benefits of structure and accomplishment.
• Social Prescribing: A growing movement in UK primary care, social prescribing involves GPs and other healthcare professionals referring patients to non-clinical community activities — such as walking groups, gardening clubs, arts activities, volunteering, and cookery classes — to address social, emotional, and practical needs. A 'link worker' helps patients identify and connect with suitable activities. Evidence for social prescribing is growing, with studies showing improvements in wellbeing, reductions in GP consultations, and improvements in depression symptoms. Social prescribing operationalises the biopsychosocial model in primary care practice.
• Digital Interventions and Apps: Online and app-based CBT programmes (e.g., MoodGym, Beating the Blues) have been shown in RCTs to reduce depression symptoms in sub-clinical and mild presentations. These are highly scalable, accessible, and remove barriers of cost and waiting lists. However, completion rates are typically low, and digital interventions are less effective than face-to-face therapy for moderate-to-severe presentations. They represent a 'first step' in a stepped-care model of mental health provision.
• Anti-Stigma Campaigns: The 'Time to Change' campaign in England (2007–2021) was the largest programme to challenge mental health stigma. Evaluations found that public attitudes toward mental health improved significantly during the campaign period, and personal stigma (internalised self-stigma among people with mental ill-health) also decreased. Reducing stigma encourages help-seeking and reduces the delay between symptom onset and accessing treatment (currently an average of 10 years for mental health problems).

Critiquing the Public Health Approach

While public health approaches are vital, they also face challenges and limitations:

• Equity Concerns: Public health interventions (e.g., gym access, arts activities) may benefit those who already have more social capital and resources, potentially widening health inequalities rather than reducing them.
• The 'Positive Psychology' Critique: An overemphasis on individual wellbeing and resilience can obscure structural causes of distress (poverty, discrimination, poor working conditions). This risks 'responsibilising' individuals for conditions that have social determinants beyond their control.
• Measurement Challenges: Outcomes like 'wellbeing' and 'resilience' are harder to measure than clinical symptoms, making it difficult to assess the effectiveness of public health initiatives rigorously.

3. Interactive & Application Activities (45 mins)

• Interactive Exercise (20 mins): In breakout rooms, students must design a public health campaign to promote mental wellbeing among university students. They should decide on a key message, a target audience, and three specific initiatives.
• Classroom Application (15 mins): Present the statement: "It is more effective to invest in public health approaches to prevent depression than to fund individual treatments." Have students use an online polling tool to show their level of agreement and then discuss their choices.

4. Distinction-Level Thinking

Analytical Question: "Critically evaluate the 'medical model' of mental illness in light of public health approaches. What are the strengths and limitations of viewing conditions like depression primarily as brain diseases?"

5. Useful Resources

• Article: Fried, E. I. (2015). The 52-symptom challenge: the impossibility of symptom-based diagnosis of depression. Journal of Affective Disorders, 184, 244-247. (A critique of diagnostic heterogeneity).
• Video: "Everything you think you know about addiction is wrong" by Johann Hari (TED Talk). A powerful argument for the role of social connection in mental health. Watch on YouTube

Session 19: Formative Assessment Workshop

Session Duration: 2 Hours (120 mins)

1. Deconstructing the Formative Assessment (45 mins)

Today we will focus entirely on the first major written assignment for this unit. Let's break down the requirements in detail.

2. Mapping the Essay to Learning Outcomes & Criteria (15 mins)

This essay directly assesses your understanding across all four learning outcomes:

• LO1: Understand the diagnosis and classification of schizophrenia.
  • AC 1.2: Evaluate biological explanations.
  • AC 1.3: Evaluate psychological explanations.
• LO2: Understand therapies for schizophrenia...
  • AC 2.1: Evaluate approaches to therapy... and their effectiveness.
• LO3: Understand the diagnosis and classification of depression.
  • AC 3.1: Analyse the way in which depression is classified.
  • AC 3.2: Evaluate biological and psychological approaches to explaining depression.
• LO4: Understand therapies for depression.
  • AC 4.1: Evaluate approaches to therapies for depression.

3. Interactive Essay Planning Workshop (45 mins)

Classroom Application: In breakout rooms, students will work together to create a detailed essay plan. Provide a shared document template for each group.

Template Structure:

1. Introduction: Hook, brief definition of both disorders, outline of the essay's structure (comparison points: diagnosis, causes, treatment).
2. Paragraph 2 (Diagnosis): Compare/contrast diagnostic criteria (e.g., DSM-5), highlighting issues like symptom overlap vs. distinct features (e.g., psychosis in schizophrenia).
3. Paragraph 3 (Causes - Schizophrenia): Briefly outline one biological (e.g., Dopamine Hypothesis) and one psychological (e.g., Family Dysfunction) explanation.
4. Paragraph 4 (Causes - Depression): Briefly outline one biological (e.g., Serotonin Hypothesis) and one psychological (e.g., Beck's Triad) explanation. Contrast the level of evidence.
5. Paragraph 5 (Treatment - Schizophrenia): Identify one treatment (e.g., Antipsychotics or CBTp) and evaluate its efficacy (strengths/weaknesses).
6. Paragraph 6 (Treatment - Depression): Identify one treatment (e.g., SSRIs or CBT) and evaluate its efficacy.
7. Conclusion: Summarise the key comparisons and contrasts, and offer a concluding thought on the complexity and distinctiveness of these disorders.

4. Q&A and Final Guidance (15 mins)

Open floor for questions regarding the assignment, referencing, or content. Remind students of the submission deadline and plagiarism policies.

Session 20: Summative Assessment Workshop & Course Review

Session Duration: 2 Hours (120 mins)

1. Deconstructing the Summative Assessment (75 mins)

The summative assessment requires a deeper, more focused analysis than the formative piece. You will choose one disorder (either depression or schizophrenia) and analyse three treatment options in depth.

Mapping to Learning Outcomes & Rubric

This task requires you to synthesize information from across the unit. For example, if you choose schizophrenia, you will be addressing:

• LO 2.1: By evaluating three approaches to therapy and their effectiveness.
• LO 2.2: By analysing the role of the clinical psychologist.
• LO 1.2 & 1.3: By explaining the biological/psychological theories that underpin the treatments you choose.

2. Unit Review and Final Q&A (45 mins)

This final part of the session is an opportunity to review the key themes of the unit and address any remaining questions.

• Key Themes Review:
  • The complexity of defining and diagnosing mental illness (LO 1.1, 3.1).
  • The interplay of biological and psychological factors (The Diathesis-Stress Model) (LO 1.2, 1.3, 3.2).
  • The strengths and limitations of the medical model and the importance of evidence-based practice (LO 2.1, 4.1, 4.2).
  • The central role of the clinical psychologist in assessment, formulation, and treatment (LO 2.2).
• Open Q&A: Students can ask any final questions about the course content or the summative assessment.